Japanese health tech startup Ubie, has signed a comprehensive collaboration with Takeda Pharmaceuticals expanding its partnership in digital transformation. The collaboration aims to guide people to appropriate medical care for rare diseases and gastrointestinal diseases.
The two companies started their partnership in 2021, promoting digital transformation for early detection of disease and guidance for appropriate medical examinations using Ubie Symptom Checker, a service for the general public with disease concerns and Ubie Patient Intake Form, a service for medical institutions.
An example of this collaboration is the rare disease called hereditary angioedema (HAE), a rare genetic disorder that causes recurrent episodes of edema in different parts of the body. There are an estimated 2000-3000 HAE patients in Japan, however, due to low levels of awareness of the disease, only about 450 cases have been diagnosed. According to a survey, at least 14 people were diagnosed from April 2021 to December 2022, after being referred to a healthcare provider through the alliance.
The companies intend to build on their achievements, expanding around rare diseases where diagnosis is an issue, as well as launching new initiatives in gastrointestinal diseases.
Click here to read the original news story.